Award Data

DESCRIPTION (provided by applicant)The major goals of this revised, SBIR Phase II application for the combined R25/R44 mechanism to complete development of a multi-media, cancer risk behavior modification intervention and to conduct a randomized controlled trial with low income patients and their primary care physicians to assess its impact. The prototype system of tools created in the Phase I is ...

DESCRIPTION (provided by applicant)The major goals of this revised, SBIR Phase II application for the combined R25/R44 mechanism to complete development of a multi-media, cancer risk behavior modification intervention and to conduct a randomized controlled trial with low income patients and their primary care physicians to assess its impact. The prototype system of tools created in the Phase I is ...

DESCRIPTION (provided by applicant): Agentase, LLC seeks follow-on Phase II Small Business Innovation Research funding to develop prototype formulations of chemically modified enzymes for the treatment and, more importantly, the prevention of organophosphorus poisonings. Several known enzymes exhibit hydrolytic activity on target organophosphorus compounds including nerve agent chemical weapons su ...

DESCRIPTION (provided by applicant): Agentase, LLC seeks follow-on Phase II Small Business Innovation Research funding to develop prototype formulations of chemically modified enzymes for the treatment and, more importantly, the prevention of organophosphorus poisonings. Several known enzymes exhibit hydrolytic activity on target organophosphorus compounds including nerve agent chemical weapons su ...

70020 Future high energy physics devices require large quantities of high performance superconducting strand at a reasonable cost. Although oxide superconductors offer superior performance and higher field than presently available metallic conductors, they are made in small quantities using labor intensive methods. Cutting these high production costs would make them technically and eco ...

Cancer chemotherapy often provides temporary clinical improvement. However, tumor cells that survive the initial treatment often develop into cancers with multiple drug resistance (MDR). This is most often mediated by increased levels of the transport protein P-glycoprotein (PgP). A related family of transporters called MRPs are expressed by most normal tissues, and have complicated the developmen ...

Current treatment protocols for AIDS involve combinations of nucleoside analogs and HIV protease inhibitors, but are not successful in curing the disease. The drug transport protein, P-glycoprotein (Pgp) effluxes a wide variety of drugs, including all FDA-approved protease inhibitors. A growing body of evidence indicates that inhibiting Pgp will enhance AIDS chemotherapy by improving the deliver ...

DESCRIPTION (provided by applicant): We propose to use power assistance as the basis for a Smart Power Assistance Module (SPAM) that provides independent power assistance to the right and left rear wheels of a manual wheelchair. The SPAM will detect obstacles near the wheelchair, and modify the forces applied to each wheel to avoid obstacles. For individuals with visual impairments that are unabl ...

DESCRIPTION (provided by applicant): Whether at home or at an institution, those unable or unwilling to ask for continence and repositioning assistance typically receive their care on a schedule that is suggested by various standards setting organizations based on the best available evidence about pressure ulcer and urinary tract infection prevention procedures. The practice of scheduling routine ...

Serenix Pharmaceuticals LLC (SPL) will develop drugs to treat impulsivity, violence and self-injurious behavior in patients with autism, Tourette's syndrome, and mental retardation. These drugs, termed serenics, stop violent behavior without disrupting normal behaviors. No other products are available for these indications. SPL required a series of vasopressin receptor antagonists from Eli Lilly C ...